Marc Blaustein
Keine laufenden Positionen mehr
Vermögen: 2 426 $ am 31.03.2024
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
George Migausky | M | 69 | 8 Jahre | |
Gustav Christensen | M | 76 | 9 Jahre | |
Mark Smith | M | 37 | 6 Jahre | |
Andrew Noh | M | - | 4 Jahre | |
Carolyn Beaty Scimemi | F | - | - | |
Mary Gray | M | 71 | 12 Jahre | |
Gregory Perry | M | 63 | 4 Jahre | |
Thomas R. Beck | M | 74 | 2 Jahre | |
William Earnest Pullman | M | 70 | - | |
Anne Marie Conway | F | - | - | |
Joseph Vittiglio | M | 52 | 2 Jahre | |
Samuel Hamood | M | 56 | - | |
Zain Kassam | M | 42 | 4 Jahre | |
Stephen S. Galliker | M | 77 | 9 Jahre | |
David Rhodes | M | - | 3 Jahre | |
Diana M. Escolar | M | 52 |
Akashi Therapeutics Inc
Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | 6 Jahre |
David Pugatch | M | - | 2 Jahre | |
Chris Weidenmaier | M | - | - | |
Aaron Sato | M | - | 7 Jahre | |
Debra Silberg | M | - | - | |
Jay Parrish | M | 49 |
Guide Therapeutics, Inc.
Guide Therapeutics, Inc. BiotechnologyHealth Technology Guide Therapeutics, Inc. develops biophotonic technology platform for the early detection of disease that leads to cancer. The company was founded by James Dahlman and Cory Sago and is headquartered in Tucker, GA. | 1 Jahre |
Alka Batycky | M | 54 | 1 Jahre | |
Patrick Taylor Horn | M | 69 | 3 Jahre | |
Eugene Williams | M | 64 |
Akashi Therapeutics Inc
Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | 4 Jahre |
Lynn G. Baird | M | 76 | 5 Jahre | |
Bryan Gillis | M | - | 1 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 26 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Marc Blaustein
- Persönliches Netzwerk